ICU Medical (ICUI) to Release Earnings on Thursday

ICU Medical (NASDAQ:ICUI) is projected to release its Q4 2025 results after the market closes on Thursday, February 19th. Analysts expect the company to announce earnings of $1.68 per share and revenue of $541.2040 million for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, February 19, 2026 at 4:30 PM ET.

ICU Medical Stock Up 2.0%

Shares of NASDAQ:ICUI opened at $144.90 on Tuesday. The firm has a 50 day simple moving average of $148.98 and a 200-day simple moving average of $135.33. ICU Medical has a twelve month low of $107.00 and a twelve month high of $165.17. The company has a current ratio of 2.45, a quick ratio of 1.19 and a debt-to-equity ratio of 0.62. The company has a market capitalization of $3.58 billion, a PE ratio of -467.40 and a beta of 0.79.

Institutional Investors Weigh In On ICU Medical

Several large investors have recently modified their holdings of the stock. Millennium Management LLC increased its stake in ICU Medical by 173.4% in the 3rd quarter. Millennium Management LLC now owns 1,089,017 shares of the medical instruments supplier’s stock valued at $130,638,000 after buying an additional 690,694 shares during the period. State Street Corp increased its stake in shares of ICU Medical by 2.8% during the fourth quarter. State Street Corp now owns 942,670 shares of the medical instruments supplier’s stock worth $134,491,000 after acquiring an additional 25,545 shares during the period. Dimensional Fund Advisors LP raised its holdings in ICU Medical by 5.5% during the fourth quarter. Dimensional Fund Advisors LP now owns 920,776 shares of the medical instruments supplier’s stock worth $131,370,000 after purchasing an additional 47,783 shares in the last quarter. Ameriprise Financial Inc. lifted its position in ICU Medical by 34.0% in the third quarter. Ameriprise Financial Inc. now owns 803,542 shares of the medical instruments supplier’s stock valued at $96,393,000 after purchasing an additional 203,746 shares during the period. Finally, UBS Group AG boosted its holdings in ICU Medical by 239.8% in the 3rd quarter. UBS Group AG now owns 386,555 shares of the medical instruments supplier’s stock valued at $46,371,000 after purchasing an additional 272,782 shares in the last quarter. Hedge funds and other institutional investors own 96.10% of the company’s stock.

Analyst Upgrades and Downgrades

ICUI has been the subject of several research analyst reports. Wall Street Zen upgraded shares of ICU Medical from a “hold” rating to a “buy” rating in a research note on Sunday. KeyCorp upped their target price on ICU Medical from $173.00 to $175.00 and gave the company an “overweight” rating in a research report on Friday, November 7th. Piper Sandler lifted their price target on ICU Medical from $153.00 to $172.00 and gave the stock an “overweight” rating in a research report on Friday, November 7th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of ICU Medical in a research report on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $175.67.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.